Author Archives: admin


Leukemia After COVID-19: Is There a Connection? – Healthline

More than 500 million people have been diagnosed with COVID-19 since late 2019. Most people who develop COVID-19 have mild disease, but theres compelling evidence that people with certain health conditions like leukemia are at elevated risk of severe disease or death.

A 2021 study presented at the 63rd American Society of Hematology Annual Meeting and Exposition found that people with blood cancer have a 17 percent chance of dying from COVID-19, significantly higher than the general population.

Its less clear if COVID-19 increases your risk of developing leukemia or other blood cancers. Some researchers think its plausible that COVID-19, in combination with other factors, could contribute to cancer development. At this time, the link remains theoretical.

Read on to learn more about how COVID-19 could, in theory, contribute to the development of leukemia.

Some types of blood cancer have been linked to infections. Its not clear if COVID-19 contributes to the development of leukemia, but scientists have found some theoretical links.

Cancer development is usually a consequence of multiple factors that drive genetic mutations in cancer cells. Its plausible that COVID-19 could predispose your body to cancer or accelerate cancer progression.

Most people with COVID-19 recover within 2 to 6 weeks, but some people have symptoms that linger for months. Its thought that the lingering effects result from chronic low grade inflammation triggered by the SARS-CoV-2 virus that causes COVID-19.

Chronic inflammation can cause DNA damage that contributes to the development of cancer. In a study published in April 2021, researchers hypothesized lingering inflammation in people with COVID-19 could increase cancer risk.

The immune response in people with COVID-19 is orchestrated by pro-inflammatory molecules linked to the development of tumors, specifically:

COVID-19 is also associated with other processes known to drive cancer formation such as:

A few case studies have reported people admitted to the hospital with leukemia shortly after developing COVID-19. However, its not clear if COVID-19 played a role or how much of a role it played. Leukemia may have developed coincidentally.

The authors of a 2022 study present a theoretical framework of how COVID-19 could influence the development of blood cancers. According to the researchers, an abnormal immune response to viral infections can indirectly trigger gene mutations that promote leukemia.

The virus that causes COVID-19 can also significantly interact with the renin-angiotensin system, which is suggested to have a role in the development of cancerous blood cells.

In a case study published in 2021, researchers present the case of a 61-year-old man who developed acute myeloid leukemia 40 days after developing COVID-19. The researchers concluded that more studies are needed to assess whether theres an association between COVID-19 and acute leukemia.

In another case study from 2020, researchers presented a man who developed COVID-19 as the first sign of chronic lymphocytic leukemia (CLL). The researchers found that the persons lymphocyte count doubled over 4 weeks, suggesting the viral infection is associated with the replication of B cells, the type of white blood cell that CLL develops in.

Some other types of viral infections have been linked to the development of leukemia.

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and its rates have been increasing. Growing evidence strongly suggests an abnormal immune response to infections early in life is responsible.

Having a human adult T-cell leukemia virus type 1 infection is linked to the development of T-cell leukemia. This virus is transmitted primarily through bodily fluids. The World Health Organization estimates that 5 to 10 million people have the viral infection.

Some types of infections have been linked to the development of another type of blood cancer called lymphoma. They include:

The FDA has approved the drug remdesivir for adults and some children with COVID-19.

At the time of writing, theres no evidence that remdesivir can cause leukemia.

In a 2021 study, a 6-year-old child with newly diagnosed ALL and COVID-19 was treated with remdesivir and convalescent plasma therapy before starting leukemia treatment.

No adverse events were linked to the therapy, and the researchers concluded this treatment could be considered in people with cancer to accelerate the resolution of the viral infection and to start cancer treatment sooner.

Some researchers have raised concerns that the antiviral drug molnupiravir, which received FDA Emergency Use Authorization on December 23, 2021, could potentially cause cancerous mutations or birth defects. Researchers are continuing to examine these potential adverse effects.

The development of blood cancer is complex. Researchers are continuing to examine whether COVID-19 infection can contribute to the development of leukemia or any other blood cancer. Some researchers have posed a theoretical link, but more research is needed.

None of the vaccines approved for use in the United States interact with your DNA or cause cancer, according to the Centers for Disease Control and Prevention (CDC). Its a myth that mRNA vaccines (Pfizer-BioNTech and Moderna) can cause changes to your DNA.

About 25 percent of blood cancer patients dont produce detectable antibodies after vaccination, according to the Leukemia & Lymphoma Society (LLS). However, the CDC continues to recommend that everyone with cancer still get vaccinated.

LLS experts say vaccination should be combined with other prevention precautions for the best protection.

People with cancer seem to be at a higher risk of severe COVID-19. According to the National Cancer Institute, people with blood cancer may have a higher risk of prolonged infection and death than people with solid tumors.

Researchers are continuing to examine the link between leukemia and COVID-19. Strong evidence suggests that people with leukemia are at an increased risk of developing severe COVID-19.

Some researchers have posed that COVID-19 could contribute to leukemia formation, but as of now, the link remains theoretical. Much more research is needed to understand the connection.

Go here to read the rest:
Leukemia After COVID-19: Is There a Connection? - Healthline

Cell Therapy Market Status and Size Report 2030 The Daily Vale – The Daily Vale

Theglobal cell therapy marketsize was valued atUSD 8.1 billion in 2021and is estimated to reachUSD 23.9 billion by 2030, growing at a CAGR of 14.5% over the forecast period. The development of precision medicine and advancements in cellular therapies in context to their efficiency & manufacturing are expected to be major drivers for the market. Moreover, the development of stem cell banking facilities and resultant enhancement of stem cells production, storage, and characterization are also expected to improve the volumetric capabilities of the market at a global level, which is anticipated to directly translate into revenue for this market at a larger level. Ongoing technological advancements in the parent and ancillary markets for stem and non-stem cells usage are expected to reinforce the demand over the forecast period. There are fewer commercialized cellular therapy products in the current market than the number of research products. This is partly due to stringent regulations and the high cost of stem cells.

Cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized as having high growth potential; as a result, many research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.

Pricing of stem cell transplantation varies from region to region. For instance, the cost of transplantation in the U.S. is higher than that in Germany or China. In March 2018, Alofisel by TiGenix received approval for marketing in Europe. This was the first allogeneic stem cell therapy to be approved in Europe. Furthermore, revenue for certain products varies for the country; for instance, products like INVOSSA received approval for marketing in Korea but have yet to receive marketing authorization in the U.S. Growth is also influenced by the commercialization of unauthorized stem cell treatments revenue generation.

Get PDF for more Professional and Technical insights:https://www.marketstatsville.com/request-sample/cell-therapy-market

Global Cell Therapy Market Definition

Therapy in which viable cells are injected, grafted, or implanted into a patient to effectuate a medicinal effect is known ascell therapy; for instance, In immunotherapy, T-cells capable of fighting cancer cells via cell-mediated immunity are transplanted, and stem cells are grafted to regenerate diseased tissues.

Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and their clinical translation. Rapid advances in stem cell research have the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. Several unknown therapies are in clinical development.

Furthermore, government and private funding agencies are constantly offering grants to support projects at various stages of clinical trials, increasing the number of ongoing clinical trials.

Research on human embryonic stem cells is ethically controversial. Harvesting embryonic stem cells involves the destruction of human embryos, raising a moral concern. In addition, stringent regulations for obtaining Intellectual Property Rights (IPR) for products or materials used in research are major restraints for commercializing these services. Ethical approval should be obtained to store cell lines and tissues in biorepositories to avoid the usage of tissue for illegal purposes or to identify proxy diseases to claim insurance. Moreover, controversies surrounding the use of embryonic stem cells for research impede the market growth in several regions

You Can Purchase Complete[emailprotected]https://www.marketstatsville.com/buy-now/cell-therapy-market?opt=2950

The study categorizes the cell therapy market based on use type and therapy type at the regional and global levels.

The analysis of the cell therapy market is based on the use of stem cells for clinical and research purposes. The research-use segment dominated the market for the global cell therapy market and accounted for the largest revenue share of 58.3% in 2021. Currently, cell therapies (stem & non-stem cells) are majorly being used for research projects, which in turn, has led to a large revenue share of this segment in 2021. Cell-based therapies are all possibilities for the replacement, repair, restoration, and regeneration of damaged tissues, cells, and organs. As an alternative to traditional treatment strategies, researchers are investing heavily in developing effective and safe cell-based treatments.

Access full Report Description,TOC, Table of Figure, Chart, etc.@https://www.marketstatsville.com/table-of-content/cell-therapy-market

As per the CGT Catapult database of clinical trials, 59 cell and gene therapy trials are ongoing in the UK. Out of all therapeutic areas, oncology has the highest number of ongoing clinical trials. T cells, CD34+ and CD133+ stem cells, mesenchymal stem/stromal cells are some predominantly employed cell types for clinical investigation. Neural cells, bone marrow mononuclear cells, fibroblasts, cornea cells, antigen-presenting cells, epithelial cells, and chondrocytes are some other cells that are being explored for the development of cell therapies.

Asia Pacificaccounts for the highestCAGR during the forecast period

Based on the regions, the global cell therapy market has been segmented across North America, AsiaPacific, Europe, South America, and the Middle East & Africa.In the Asia Pacific, the market for cell therapy is anticipated to witness a lucrative growth rate of 15.5% over the forecast period. Advancements in stem cell therapy in Asian countries are observed to be better than those in the U.S. This has resulted in Asia leading stem cell research. Several stem cell consortiums in Asian countries aim to ensure coordinated and focused R&D programs. Moreover, patients from western countries migrate to Asian countries for treatment, owing to the flexible legal framework.

Companies from Japan, South Korea, India, China, Taiwan, Singapore, and the rest of Asia were active participants in the conference. In addition, the large regional population and untapped potential present in the region have resulted in global firms entering the market. Moreover, this region offers relatively inexpensive manufacturing & operating units for conducting research. These factors are expected to play a major role in expanding the stem cell market in this region.

Request For Report Description @https://www.marketstatsville.com/cell-therapy-market

The cell therapy market is mildly concentrated in nature with few numbers of global players operating in the market such as Kolon TissueGene, Inc., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., Castle Creek Biosciences, Inc., MEDIPOST, Osiris Therapeutics, Inc., PHARMICELL Co., Ltd, Tameika Cell Technologies, Inc., Cells for Cells, NuVasive, Inc., Vericel Corporation, and Celgene Corporation

Continue reading here:
Cell Therapy Market Status and Size Report 2030 The Daily Vale - The Daily Vale

New York’s Buzziest Plastic Surgeon Reveals Her Anti-Aging Skincare Routine – InStyle

Each product we feature has been independently selected and reviewed by our editorial team. If you make a purchase using the links included, we may earn commission.

In some sci-fi fantasy future, with a simple pill or tincture, aging will be a concern of the past and everyone, and quite literally their mother, will miraculously look like their 21-year-old selves forever. But until that (frankly eerie) day arrives, we're left depending on the tools available to us now, some of which are quite sophisticated as it is; cosmetic enhancements, lasers, and most widely skincare lend a hand in turning back the clock on biologically and environmentally induced signs of aging.

No one knows the power we have to control our own aging process better than a plastic surgeon, and every plastic surgeon knows that process starts right at home in our bathroom vanities. Dr. Melissa Doft is one of New York City's most buzzed-about plastic surgeons, having been listed as one of New York magazine's top physicians from 2018 to 2022 and one of Castle Connolly's top doctors of 2022, not to mention being quoted in countless publications including Byrdie, Wall Street Journal, and, yes, even InStyle. Now, she's sharing her very own anti-aging skincare routine with InStyle, and we're excited by how much of it is available outside the closed doors of aesthetics offices.

"I think I may be getting to the age when it is more of a battle than a concern," says Dr. Doft of her approach to anti-aging skincare. As for what ingredients she looks for in her skincare, she highlights retinol as the most important: "Everyone with aging concerns should use it." Aside from that, she uses vitamin C to "brighten and even my skin tone" and hyaluronic acid for maximum hydration, "as I never have time during the day to drink enough water." She goes on to champion peptides, which she says can "help firm the skin and reduce fine lines."

Though Dr. Doft has been able to sample countless formulas from pharmaceutical companies and luxury brands, her at-home routine boils down to just a few choice products; the Clarins Super Restorative Treatment Essence being one of them for morning use. "I do not wear makeup every day, so having glowing skin is very important." She then applies a stem cell C serum from her office, and while the exact product isn't available online, we did find this promising alternative from clean beauty brand Indie Lee.

If you're ready to take your skin even further, Dr. Doft shared that her favorite anti-aging procedures offered at her Manhattan clinic are microneedling with radiofrequency, which makes skin look "better, tighter, and with smaller pores," as well as the CO2 Fraxel laser, which she loves "because it allows me to heal over the weekend and have glowing skin the following week."

Whether or not you opt for in-office solutions, there's still so much impact you can make on your skin with a simple anti-aging skincare routine. Steal Dr. Doft's expert regimen below.

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

this link is to an external site that may or may not meet accessibility guidelines.

Read more:
New York's Buzziest Plastic Surgeon Reveals Her Anti-Aging Skincare Routine - InStyle

In first, Verve gets clearance to test base editing inside the body – BioPharma Dive

Dive Brief:

New Zealands decision to clear human testing represents a notable achievement for Verve and another important milestone for the type of gene editing technology the company is developing. Known as base editing, it's a potentially more precise way to modify genes, enabling scientists and drugmakers to change single DNA "letters."

Base editing builds on the progress made with CRISPR-based editing and has rapidly moved from laboratories into clinics. Beam Therapeutics, which licenses technology to Verve, won U.S. approval in November to begin a clinical trial of a base editing therapy for sickle cell disease. Unlike Beam's treatment, Verve's is designed to do its work inside the body, rather than on cells taken out of the body and modified in a lab. It's now the third inside-the-body gene editing treatment to enter human trials, following experimental drugs from Intellia Therapeutics and Editas Medicine.

While Tuesday's news is a milestone, Verve has a long way to go. Though the company is initially targeting a rare condition, it ultimately seeks to conquer one of the most prevalent diseases in the world. Even if the technology succeeds, Verve will have to persuade doctors and patients to adopt a potentially expensive genetic therapy when other, comparatively cheaper drugs exist to lower cholesterol and prevent some of the worst effects of heart disease.

For example, drugmakers in recent years have introduced several injectable medicines that specifically target PCSK9. While they had dramatic effects on cholesterol levels, insurers balked at the initial prices. The drugs are mostly used for patients at the most risk of a heart attack.

Verve CEO Sekar Kathiresan argues that his company's approach, if proven in clinical trials, offers an approach that will not only save lives, but also money for the healthcare system. He envisions a therapy akin to a vaccine for heart attacks thats not dependent on taking pills or receiving injections for life.

Verve has been publicly traded for less than a year, having raised $267 million in an initial public offering in June. While its IPO was one of the most successful in the biotech industry in 2021, the companys share price has tumbled along with its biotech peers in recent months. Once soaring above $70, Verve shares now trade around $13 apiece.

Link:
In first, Verve gets clearance to test base editing inside the body - BioPharma Dive

Precision Cancer Therapies Market to Witness Robust Expansion by 2029 | Abbott Laboratories, Bayer HealthCare SMU Daily Mustang – SMU Daily Mustang

California (United States) Precision Cancer Therapies Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share, and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs, and Tables) of this report @:

Some of the Top companies Influencing this Market include:

Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex Pharmaceuticals, Hospira, Boehringer Ingelheim, AstraZeneca, Aveo Pharmaceuticals.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global

Global Precision Cancer Therapies Market Segmentation:

Market Segmentation: By Type

Hormone Therapy, Immunotherapies, Targeted Therapy, Monoclonal Antibody Therapy, Gene Therapy

Market Segmentation: By Application

Hospitals, Diagnostic Centers, Oncology Clinics, Research Institutes

The report provides insights on the following pointers:

Market Penetration: Comprehensive data on the product portfolios of the top players in the Precision Cancer Therapies market.

Product Development/Innovation: Detailed information about upcoming technologies, R&D activities, and market product debuts.

Competitive Assessment: An in-depth analysis of the markets top companies market strategies, as well as their geographic and business segments.

Market Development: Information on developing markets in its entirety. This study examines the market in several geographies for various segments.

Market Diversification: Extensive data on new goods, untapped geographies, recent advancements, and investment opportunities in the Precision Cancer Therapies market.

Get Up to 30% Discount on the first purchase of this report @:

Global Precision Cancer Therapies market Report Scope:

The cost analysis of the Global Precision Cancer Therapies Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Key questions answered in this report:

Table of Contents

Global Precision Cancer Therapies Market Research Report 2022 2029

Chapter 1 Precision Cancer Therapies Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Precision Cancer Therapies Market Forecast

Buy Exclusive Report:

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

+1 775 237 4147

See the original post:
Precision Cancer Therapies Market to Witness Robust Expansion by 2029 | Abbott Laboratories, Bayer HealthCare SMU Daily Mustang - SMU Daily Mustang

Canavan Disease Treatment Market to Witness Robust Expansion throughout the Forecast Period to 2028 – Digital Journal

Canavan Disease Treatment market document takes into consideration the market type, size of the organization, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa to analyse the data. The report also describes all the major topics of the market research analysis that includes market definition, market segmentation, competitive analysis, major developments in the market, and excellent research methodology. Clients can reveal the best opportunities to be successful in the market with an excellent practice models and method of research used while creating Canavan Disease Treatment market report.

Download Exclusive Sample (350 Pages PDF) Report:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-canavan-disease-treatment-market

Key Segmentation:

By Treatment (Gene Therapy, Drug Therapy, Others)

By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

List of the Leading Companies Profiled in the Canavan Disease Treatment Market are:

Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Sanofi, F. Hoffmann-La Roche Ltd., and Amgen, Inc

Brief Overview on Market:

The report covers profiling of key market players with overall business operations, news coverage, product portfolio, geographic presence, and financial status. Value chain analysis is provided, which is combined with the competitive landscape of key players of the market. Market size and forecast of the Canavan Disease Treatment market for the period has been given. Global presence of the market, market dynamics, and evaluation by upstream and downstream of raw materials have been discussed.

The Global Canavan Disease Treatment Marketresearch to provide market definition, the report neatly researches market driving factors. The report has been created after detailed and exhaustive studies several factors into consideration like monetary, ecological, social, mechanical, and political status of a particular demography. Moreover, it offers noteworthy data along with future forecast and thorough analysis of the market on a global and regional level. Expert solutions combined with potential capabilities make this Canavan Disease Treatment market report outshining.

Key stakeholders in Market including industry players, policymakers, and investors in various countries have been continuously realigning their strategies and approaches to implement them in order to tap into new opportunities. Price point comparison by region with the global average price is also considered in the study.

Canavan Disease Treatment Market Segments by Geography

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

The key countries in each region are taken into consideration as well, such as United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Highlights of the Report

In-depth analysis of various insights, namely, Canavan Disease Treatment Market trends, growth drivers, opportunities, and other related challenges.

Comprehensive details of key market players, their core competencies, and market shares.

The potency of suppliers and buyers to make better business decisions.

Lists out the market size in terms of volume.

Key Highlights from the Canavan Disease Treatment Market Outlook Report:

Elaborated scenario of the parent marketTransformations in the Canavan Disease Treatment market dynamics, Canavan Disease Treatment market trends, growth drivers, opportunities, and other related challenges.Detailed segmentation of the target marketHistorical, current and forecast of Canavan Disease Treatment market size based on value and volumeLatest industry developments and Comprehensive details of key market players, their core competencies, and market shares.Competitive analysis of Canavan Disease Treatment MarketStrategies adopted by the Canavan Disease Treatment industry key players and product developments madePotential and niche segments, along with their regional analysis & surveyUnbiased analysis on market growth and Lists out the market size in terms of volume of Canavan Disease Treatment marketUp-to-date and must-have intelligence for the market players to enhance and sustain their competitiveness

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-canavan-disease-treatment-market

Comprehensive Market Coverage as part of its offering, this report includes:

COVID-19 Testing Markets, Current, Future and Projected.

Impact onCanavan Disease Treatment Market, 2021 and 2022

350+ Page Report Based on Vendor Reporting, Interviews, Vendor Activities

Detailed Market Chapters with 2022 Market Estimates

Market Segment Projections to 2028

Regional Breakouts Including Country Canavan Disease Treatment Markets

Coverage of Growth Markets

Superior Company Profiles of Top Tier Companies and Hundreds of Smaller Concerns

Industry-Standard Business Planning Tools

Coverage of Trends and Market Estimates for Essential Canavan Disease Treatment Segments

Buy Full Report:https://www.databridgemarketresearch.com/reports/global-canavan-disease-treatment-market

The data provided in the Canavan Disease Treatment Demand report offers comprehensive analysis of important industry trends. Industry players can use this data to strategize their potential business moves and gain remarkable revenues in the upcoming period.

The report covers the price trend analysis and value chain analysis along with analysis of diverse offering by Key vendors. The main motive of this Survey report is to assist enterprises to make data-driven decisions and strategize their business moves.

Browse Similar Reports:

https://www.marketwatch.com/press-release/rotavirus-prophylaxis-market-scope-and-overview-growth-study-future-trends-and-top-players-by-forecast-to-2027-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/specimen-containers-market-2022-size-future-trends-global-regions-impact-of-covid-19-gross-margin-regional-demand-and-forecast-to-2027-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/sialorrhea-market-share-industry-growth-trend-drivers-challenges-key-companies-by-2027-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/europe-tumor-ablation-market-to-witness-robust-expansion-throughout-the-forecast-period-to-2029-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/life-science-software-market-reportknow-the-latest-innovations-and-trends-to-2027-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/magnetic-resonance-imaging-mri-systems-market-size-share-growth-trends-and-forecast-20222028-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/bone-spur-market-forecast-business-opportunities-size-share-scope-forecast-to-2028-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/cyclin-dependent-kinase-inhibitor-market-size-2028by-application-type-manufacturers-across-north-america-europe-apac-south-america-mea-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/celiac-drugs-market-size-share-and-forecast-2028-segmentation-key-insights-and-company-profiles-takeda-pharmaceutical-company-limited-amgen-inc-cour-pharmaceuticals-development-company-inc-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/smart-health-watches-market-production-size-key-trends-challenges-top-key-players-and-forecast-to-2027-2022-05-09?mod=search_headline

https://www.marketwatch.com/press-release/muckle-wells-syndrome-market-growth-share-trend-business-opportunities-manufacturers-and-research-methodology-by-2027-2022-05-09?mod=search_headline

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Go here to see the original:
Canavan Disease Treatment Market to Witness Robust Expansion throughout the Forecast Period to 2028 - Digital Journal

Phenylketonuria (PKU) Treatment Market Research Study, Future Prospects and Growth Drivers to 2029 | Top Key Vendors American Gene Tech, Abbott,…

The Global Phenylketonuria (PKU) Treatment Market is expected to gain market growth at a potential rate of 10.95% in the forecast period of 2022 to 2029.

Todays businesses are more inclined towards the market research report because it supports with the improved decision making, more revenue generation, prioritize market goals and achieve profitable business. Analysis and estimations derived through the huge information collected in this market report are extremely essential when it comes to dominating the market or creating a mark in the market as a rising emergent. Global Phenylketonuria (PKU) Treatment Market report is all-inclusive of the data which includes market definition, classifications, applications, engagements, market drivers and market restraints that are derived from SWOT analysis.

The leading Phenylketonuria (PKU) Treatment Market research report provides market definition in the form of market driving factors and market restraints which aids in estimating the requirement of particular product where several aspects have to be considered. Similarly, market segmentation is another significant parameter that categorises the market depending upon application, vertical, deployment model, end-user, and geography etc. To carry out competitive analysis, various strategies of the major players in the market have been taken into account that range from new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others which lead to an ascend of their footprints in the market. The winning Phenylketonuria (PKU) Treatment Market report includes market shares for global, Europe, North America, Asia Pacific and South America.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-phenylketonuria-pku-treatment-market .

According to market research study, Phenylketonuria is defined as a rare inherited genetic disorder that leads to the increase in levels of phenylalanine in blood. Phenylalanine is an amino acid which is comprised of proteins obtained from food and diet. Phenylalanine hydroxylase enzyme converts phenylalanine in to tyrosine amino acid in human body.

Some of most important key factors driving the growth of the Global Phenylketonuria (PKU) Treatment Market are incidence rate of phenylketonuria, rise in the research in the field of genomics and bioinformatics, rise in the awareness amongst the people, increase in the research in the field of genomics and bioinformatics and increase in the development and commercialization of new drugs.

Global Phenylketonuria (PKU) Treatment Market Segmentation:

Based on the Type, the phenylketonuria (PKU) treatment market is segmented into hyperphenylalaninemia, mild PKU and moderate or variant and classic PKU.

On the basis of Drugs Type, the phenylketonuria (PKU) treatment market is segmented into kuvan, sapropterin, palynziq, pagvaliase and biopten.

On the basis of Therapy Type, the phenylketonuria (PKU) treatment market is segmented into gene therapy and dietary therapy.

On the basis of Route of Administration, the phenylketonuria (PKU) treatment market is segmented into oral, intravenous, subcutaneous and others.

On the basis of End-User, the phenylketonuria (PKU) treatment market is segmented on the basis of end-user into hospitals, homecare, specialty clinics and others.

Regionally, North America dominates the phenylketonuria (PKU) treatment market due to rise in the favorable regulations, rising government initiatives for the treatment of PKU and continuous research and development and commercialization of novel drugs in this region. Europe is the expected region in terms of growth in phenylketonuria (PKU) treatment market due to rise in the awareness amongst the people and increase in the research in the field of genomics and bioinformatics in this region.

Access Complete Report @ https://www.databridgemarketresearch.com/reports/global-phenylketonuria-pku-treatment-market

Top Major Key Players in the Global Phenylketonuria (PKU) Treatment Market:

DAIICHI SANKYO COMPANY LIMITED

Ajinomoto Cambrooke Inc.

American Gene Technologies Inc.

Ultragenyx Pharmaceutical

Danone Nutricia

Reckitt Benckiser Group plc

Abbott

Promin Metabolics

Som innovation biotech SL

Synthetic Biologics Inc.

Nestle

Codexis

BioMarin

Erytech Pharma

Report contents include

1 Analysis of the Phenylketonuria (PKU) Treatment Market includes revenues, future growth, market outlook 2 Historical data and forecast 3 Regional analysis including growth estimates 4 Analyses the end user markets including growth estimates. 5 Profiles on Phenylketonuria (PKU) Treatment including products, sales/revenues, and market position 6 Phenylketonuria (PKU) Treatment Market structure, key drivers and restraints

Get a Complete TOC of Global Phenylketonuria (PKU) Treatment Market Report 2022 @ https://www.databridgemarketresearch.com/toc/?dbmr=global-phenylketonuria-pku-treatment-market .

Global Phenylketonuria (PKU) Treatment Market: Table of Contents

1 Report Overview 2022-2029

2 Global Growth Trends 2022-2029

3 Competition Landscape by Key Players

4 Global Phenylketonuria (PKU) Treatment Market Analysis by Regions

5 Global Phenylketonuria (PKU) Treatment Market Analysis by Type

6 Global Phenylketonuria (PKU) Treatment Market Analysis by Applications

7 Global Phenylketonuria (PKU) Treatment Market Analysis by End-User

8 Key Companies Profiled

9 Global Phenylketonuria (PKU) Treatment Market Manufacturers Cost Analysis

10 Marketing Channel, Distributors, and Customers

11 Market Dynamics

12 Global Phenylketonuria (PKU) Treatment Market Forecasts 2022-2029

13 Research Findings and Conclusion

14 Methodology and Data Source

Get Our More Trending Research Report Here:

1 Asia-Pacific Interventional Neurology Devices Market Trends and Forecast to 2029

2 Europe Beauty Devices Market Industry Trends and Forecast to 2029

3 Global Cistanche Deserticola Market Industry Trends and Forecast to 2029

4 Global Deflectable Catheters Market Industry Trends and Forecast to 2029

5 Global Dental Crown Market Industry Trends and Forecast to 2029

6 Global Epidermal Growth Factor Receptor Inhibitors Market Industry Trends and Forecast to 2029

7 Global Hepatitis C Diagnosis and Treatment Market Industry Trends and Forecast to 2029

8 Global Insulin API Market Industry Trends and Forecast to 2029

9 Global Laparoscopic Electrodes Market Industry Trends and Forecast to 2029

10 Global Sleep Bruxism Market Industry Trends and Forecast to 2029

11 Global Small Molecule Targeted Cancer Therapy Market Industry Trends and Forecast to 2029

12 Global Spasticity Treatment Market Industry Trends and Forecast to 2029

13 Global Surgical Clips Market Industry Trends and Forecast to 2029

14 Global Tachycardia Drugs Market Industry Trends and Forecast to 2029

15 Global Vagus Nerve Stimulation Market Industry Trends and Forecast to 2029

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [emailprotected]

Follow this link:
Phenylketonuria (PKU) Treatment Market Research Study, Future Prospects and Growth Drivers to 2029 | Top Key Vendors American Gene Tech, Abbott,...

Sleep deprivation may increase the risk of eye disease – Medical News Today

While scientists know that sleep deprivation has a negative effect on the body, they are still researching how it affects different organs.

Researchers from China and the U.S. recently published a study in Stem Cell Reports on how poor sleep can affect the eyes. They found that sleep deprivation can affect both stem cells in the cornea and the tear film surface of the cornea.

Getting a good nights sleep on a regular basis is important, but according to the Centers for Disease Control and Prevention (CDC), more than one-third of adults dont get enough sleep. Doctors recommend that adults get at least 7 hours of sleep per night.

The CDC reports that not getting enough sleep can cause a myriad of health issues, such as having a higher risk for obesity, developing diabetes, and high blood pressure.

Part of the issue contributing to so many people not getting enough rest is having a sleep disorder. The National Institutes of Health reports that around 40 million Americans have a sleep disorder.

Some sleep disorders include:

For those who are not affected by a sleep disorder, the best way to regularly get enough sleep is to practice good sleep hygiene. People can accomplish this by going to bed at the same time every night, avoiding screens 1-2 hours before bed, and not drinking alcohol before bed.

The researchers in this study used mice to learn more about how sleep deprivation affects the eyes.

According to the authors, the cornea is the clear front surface of the eye. They also write that the cornea has an overlying tear film that helps keep the eyes comfortable and offers protection against infection.

The researchers were interested to find out to what degree sleep deprivation may affect stem cells in the cornea.

As Dr. Neil Neimark, a board certified family physician in functional medicine who applies stem cell therapy in his practice, noted in a TEDx Talks podcast, stem cells have healing power and all tissue repair in the body is initiated by stem cells.

The researchers of the current study assessed gene expression in the mice after 2 days of sleep deprivation and then after 10 days of sleep deprivation.

At the 2-day point, the researchers found that 287 genes were significantly upregulated and 88 were downregulated in corneas. At the 10-day point, they saw 272 significantly upregulated genes and 150 downregulated genes.

The authors tested the mice after 1 and 2 months of further sleep deprivation and found that the transparency of the cornea was reduced and the ocular surface was rough.

While stem cells were upregulated in the sleep-deprived mice early on, it eventually led to what the authors referred to as an early manifestation of limbal stem cell deficiency. After being upregulated for so long, the stem cells became depleted.

Short-term consequences of insufficient sleep or delayed sleep cause ocular discomfort, including dryness, pain, pruritus, and hyperemia of the eye, the authors note.

Despite these issues, the authors observed that treating the mice with damaged corneas with eye drops containing antioxidants helped restore the eye health of the mice.

Dr. Howard R. Krauss, a surgical neuro-ophthalmologist and director of Neuro-Ophthalmology for the Pacific Neuroscience Institute at Providence Saint Johns Health Center in Santa Monica, CA, who was not involved in the study, spoke to Medical News Today about the findings.

The design of the study was to study chemical and cellular changes in the ocular surface of sleep-deprived mice, revealing indeed that there are damaging effects, which shed light on mechanisms which may be at play in human symptoms and disease, Dr. Krauss said.

While Dr. Krauss thought the study was helpful at showing how sleep deprivation can potentially affect humans, he noted a limitation.

A weakness of the study is the methodology by which sleep deprivation is induced in mice, who are in cages, perched on sticks to remain above a water-filled bottom when the mouse falls asleep, it falls into the water, immediately wakes up, and climbs back up onto the stick, Dr. Krauss explained.

Dr. Krauss said the method used to induce sleep deprivation raises the question of how much of the chemical and cellular change they observed was purely secondary to sleep deprivation and how much may be a stress reaction to the means by which sleep deprivation has been engineered.

Nonetheless, the study refocuses our attention on sleep deprivation and leads us to think that the scope of damaging effects of sleep deprivation may be far [broader] than we realize, he said.

As such, the human need for sleep for maintenance of good health becomes more obvious every day. Dr. Howard R. Krauss

Read more:
Sleep deprivation may increase the risk of eye disease - Medical News Today

Experts see blood stem cell transplant as a curative treatment for thalassemia – India Today

Baby Bhushra Naqeeb, an 11-year-old girl who has suffered from thalassemia since the age of 6 months, recently suggested an allogeneic stem cell transplant as her only chance of survival after over 10 years of blood transfusion. Finally, with the support from the DKMS-BMST thalassemia programme, she underwent stem cell transplantation in October 2021 under Dr. Sachin Jadhav, HCG (HeathCare Global Enterprises Ltd.) group of hospitals. Post the transplant, Bhushra is able to lead a normal life as she also attends regular school.

India is also known as the Thalassemia capital of the world. The country has the largest number of children with thalassemia major with over 10,000 children born with it every year. According to the World Health Organisation (WHO), over four million Indians are thalassemia carriers and more than 1,00,000 are patients. Parents, who are usually asymptomatic, are the carriers of this disease and have a 25% chance of passing this disease to their children.

Patients suffering from thalassemia are required to undergo lifelong regular blood transfusions to maintain their hemoglobin levels. However, it can now be cured with stem cell transplantation.

THE ONLY CURE

Dr. Sunil Bhat, Director and Clinical Lead, Pediatric Hematology, Oncology and Blood & Marrow Transplantation, Narayana Health said, Thalassemia patients are mostly children who go through painful blood transfusion for several years in their life. Blood transfusions have their own challenges and risks for the patients. A stem cell transplantation is currently the only curative option available for this condition. Recent data shows a more than 90% success rate of stem cell transplantation in patients who have HLA (Human Leukocyte Antigen) matched stem cell donors.

In a blood stem cell transplant, stem cells are collected from the blood of the donors and transplanted into the thalassemia patient after their bone marrow has been destroyed. Only 30% of patients who need transplants have a fully HLA-matched donor in their family, while the rest of them depend on an unrelated donor.

Shobha Tuli, the founder of the NGO - Thalassemics India, President-Federation of Indian Thalassemia Associations, says At present, stem cell transplant is the only curative treatment available for Thalassemia patients. If not cured on time, such patients are dependent on blood transfusions all throughout their lives along with other expensive treatments & regular investigations. Thalassemia Bal Sewa Yojna is a unique project initiated by the Ministry of Health & Family Welfare, Govt. of India. Under this scheme, a patient can get financial aid up to Rs. 10 lakhs from Coal India Ltd. DKMS has offered us an opportunity to get free HLA tests done in the country. This enables the patients to check if they have a matched sibling.

LOW AWARENESS

There are around 270 million Thalassemia patients in the world but awareness about the disease is alarmingly less. Symptoms of Thalassemia usually start at 4 to 6 months of age and usually present with lethargy, poor feeding, progressive pallor, poor weight gain and sometimes vomiting and diarrhoea. On examination, the babies are pale and have liver and spleen enlargement.

Patrick Paul, CEO, DKMS BMST Foundation India, says, It is our mission to support blood cancer, and other blood disorders such as Thalassemia patients in India, for which we have initiated the DKMS-BMST Thalassemia programme. Under this programme, DKMS-BMST collaborates with local NGOs and transplantation clinics to organise camps where paediatric thalassemia patients and their siblings travelling from afar places in India to give buccal swab samples for free HLA typing. Samples from the camps are analysed in the DKMS laboratory based out of Germany and clinical matching reports of the same are provided. In cases where there is no matching sibling for a sick child, we also support unrelated donor searches for patients. Since the inception of the programme, so far, 7,162 HLA typings have been facilitated by DKMS-BMST.

HOW YOU CAN HELP

Dr. Bhat also added, A successful blood stem cell transplant depends on a perfect HLA tissue match. Patients and donors of Indian origin have unique HLA characteristics that are severely under-represented in the global database, which makes the probability of finding a suitable donor even more difficult. Indian patients mainly require an Indian tissue match. This calls for increased awareness and the need to encourage many more people in India to register as potential blood stem cell donors.

To register as a potential blood stem cell donor, healthy individuals between 18-50 years of age can register at: dkms-bmst.org/register

All it takes is five minutes of your time and a simple 3-step process:

Step 1: Visit the site, fill in an online form and you will receive a DIY swab kit at home.

Step 2: Once you receive the swab kit, fill out the consent form and take a tissue sample from the inside of your cheeks with 3 cotton swabs provided in the kit.

Step 3: Send back your swab sample in the pre-paid envelope provided.

The DKMS laboratory will then analyse your tissue type and your details will be available in the global search for blood stem cell donors. If you do come up as a suitable donor, DKMS-BMST will get in touch with you straight away. Once you come up as a match, blood stem cells will be obtained from the bloodstream using a procedure called Peripheral Blood Stem Cell Collection, which is similar to a blood donation wherein only your stem cells are taken. This is a safe, non-surgical outpatient procedure.

READ MORE | JNU biologists identify a new way to better treat kala-azar

Originally posted here:
Experts see blood stem cell transplant as a curative treatment for thalassemia - India Today

Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their…

Aileron Therapeutics, Inc.

Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia)

New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles and their stem cells

ALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversible stem cell damage

Ailerons precision medicine-based approach is designed to selectively protect normal, healthy cells from chemotherapy while ensuring chemotherapy cannot protect cancer cells

Ailerons ongoing non-small cell lung cancer (NSCLC) clinical trial and upcoming breast cancer clinical trial will evaluate ALRN-6924s protection against chemotherapy-induced bone marrow toxicities and other side effects, including alopecia

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients lives, today announced a late-breaking oral presentation at the upcoming Society for Investigative Dermatology (SID) Annual Meeting, which will be held May 18 21, 2022 in Portland, Oregon. The presentation will highlight new non-clinical data developed in collaboration with Professor Ralf Paus, M.D., DSc, FRSB and his colleagues at the Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery at the University of Miami Miller School of Medicine. This collaboration has generated promising ex vivo data demonstrating that ALRN-6924 protected human hair follicles and their stem cells from chemotherapy-induced acute and permanent damage. Details of the presentation are as follows:

Title:

ALRN-6924, a dual inhibitor of MDMX and MDM2, protects human scalp hair follicles and their epithelial stem cells from paclitaxel-induced toxicity (LB1018)

Presenter:

Jennifer Gherardini, Ph.D.; Paus Laboratory, University of Miami Miller School of Medicine

Date:

Thursday, May 19th

Time:

8:45 AM 11:15 AM PT

Session:

Late-Breaking Abstract Concurrent Session

Chemotherapy-induced toxicities range from severe and life-threatening to those that impact and diminish patients quality of life, sometimes long after chemotherapy has been completed. These toxicities occur because chemotherapy destroys normal, healthy cells while simultaneously destroying cancer cells, said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer at Aileron. Previously, we showed chemoprotection against severe bone marrow toxicities in small cell lung cancer patients receiving topotecan and demonstrated in healthy volunteers the mechanism of action cell cycle arrest underlying this chemoprotection benefit. We are excited to now present new data that may suggest ALRN-6924s ability to also protect against chemotherapy-induced hair loss, another devastating chemotherapy-induced side effect for millions of cancer patients.

Dr. Paus commented, These results got us quite excited as they directly follow in the footsteps of our prior work that showed arresting the cell cycle can have a strong protective effect against taxane-induced hair follicle damage. Until our research with ALRN-6924, we had not come across a cell cycle arrest-inducing drug that is in clinical testing for protection of normal cells without protecting cancer cells. Thus, ALRN-6924 invites a very promising and completely novel selective protection approach. In addition, we found that ALRN-6924 may exert some additional benefits that could reduce the risk of long-term damage of human hair follicle stem cells by taxanes.

Story continues

Aileron is currently developing ALRN-6924, a first-in-class MDM2/MDMX dual inhibitor, to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapys attack on cancer cells. ALRN-6924 is designed to activate p53 in normal cells, which in turn upregulates p21, which pauses cell cycle in normal cells but not in p53-mutated cancer cells. The companys vision is to bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy.

About the Findings

Taxanes, such as paclitaxel and docetaxel, are known to cause severe and often permanent chemotherapy-induced alopecia. Over 90% of patients treated with this chemotherapy class experience alopecia, and approximately 10% (paclitaxel) to 25% (docetaxel) of patients experience permanent alopecia. Dr. Paus and his team previously demonstrated that paclitaxel damages human scalp hair follicles by inducing massive mitotic defects and apoptosis in hair matrix keratinocytes as well as bulge stem cell DNA damage, and that pharmacological induction of transient cell cycle arrest can protect hair follicles and stem cells (Purba et al. EMBO Molecular Medicine 2019). Aileron previously conducted in vitro studies showing that ALRN-6924 protected human fibroblasts in cell culture from multiple chemotherapies, but not p53-mutant breast cancer cells.

In the new non-clinical findings to be presented at the SID meeting, when organ-cultured anagen (i.e., active growth phase) scalp hair follicles from two human donors were pre-treated with ALRN-6924 or vehicle (i.e., placebo), followed by paclitaxel or vehicle, ALRN-6924 significantly increased the number of p21-positive hair matrix keratinocytes and bulge stem cells compared to vehicle or paclitaxel alone, confirming cell cycle arrest ex vivo. Further, pretreatment of paclitaxel-treated human hair follicles with ALRN-6924, led to a reduction in the number of melanin clumps, a marker of hair follicle cytotoxicity and dystrophy, as well as a reduction in apoptosis, pathological mitosis, and DNA damage. Aileron believes that these findings support clinical investigation of ALRN-6924 to prevent both acute and permanent chemotherapy-induced alopecia, in addition to its ongoing evaluation of ALRN-6924 to protect against chemotherapy-induced bone marrow and other toxicities.

About Ailerons Clinical Trials of ALRN-6924

Aileron is on track to initiate a Phase 1b randomized, controlled trial of ALRN-6924 in patients with p53-mutated ER+/HER2- neoadjuvant breast cancer in 2Q 2022. The planned breast cancer trial will evaluate ALRN-6924s protection against chemotherapy-induced bone marrow toxicities, as well as other toxicities, including alopecia, in patients with p53-mutated ER+/HER2- breast cancer treated with a doxorubicin plus cyclophosphamide and docetaxel chemotherapy regimen.

The company is currently enrolling patients in a Phase 1b randomized, double-blind, placebo-controlled trial evaluating ALRN-6924s protection against chemotherapy-induced bone marrow and other toxicities in patients with advanced p53-mutated non-small cell lung cancer undergoing treatment with first-line carboplatin plus pemetrexed with or without immunotherapy. While patients in this trial are monitored for alopecia, historically, only a small percentage of patients treated with carboplatin plus pemetrexed experience acute alopecia. Aileron is on track to report interim results on the first 20 patients enrolled in the NSCLC trial in June 2022 and topline results on 60 patients in 4Q 2022.

About Aileron Therapeutics

Aileron is a clinical stage chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients lives. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy.

Our vision is to bring chemoprotection to all patients with p53-mutated cancers, which represent approximately 50% of cancer patients, regardless of type of cancer or chemotherapy. Visit us at aileronrx.com to learn more.

Forward-Looking Statements

Statements in this press release about Ailerons future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the potential of ALRN-6924 as a chemoprotective agent, including its ability to prevent both acute and permanent chemotherapy-induced alopecia, and the Companys strategy and clinical development plans. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Ailerons cash resources will be sufficient to fund its continuing operations for the periods anticipated or with respect to the matters anticipated; whether initial results of clinical trials will be indicative of final results of those trials or results obtained in future clinical trials, including trials in different indications; whether ALRN-6924 will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will be accepted by and warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether ALRN-6924 will receive approval from regulatory agencies on a timely basis or at all or in which territories or indications ALRN-6924 may receive approval; whether, if ALRN-6924 obtains approval, it will be successfully distributed and marketed; what impact the coronavirus pandemic may have on the timing of our clinical development, clinical supply and our operations; and other factors discussed in the Risk Factors section of Ailerons annual report on Form 10-K for the year ended December 31, 2021, filed on March 28, 2022, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Investor Contact: Stern Investor Relations Alexander Lobo alex.lobo@sternir.com

Media Contact: Liz Melone 617-256-6622

Original post:
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their...